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INTRODUCTION
In renal ischemia and reperfusion in-
jury (IRI), inflammation results in changes
in the endothelial cell phenotype. These
changes enhance leukocyte adhesion, en-
trapment, and transmigration, ultimately
compromising the regional blood flow (1).
In kidney transplantation, IRI is impli-
cated as one of the potential contributors
to the development of chronic allograft
nephropathy, now recognized as graft tu-
bular atrophy/interstitial fibrosis, the
main cause of graft loss after the first year
of transplantation (2,3).
In the initial period of reperfusion,
there is a rapid increase in proinflamma-
tory cytokines, such as a tumor necrosis
factor α (TNF-α) and interleukin (IL)-1β,
induced in part by infiltrating mononu-
clear and endothelial cells (4,5). There are
also significant increases in the syntheses
of leukotrienes and cyclooxygenase
(COX) (3,6).
COX 1 and  2 can be detected in kidney
tissue subjected to IRI, and recent data
from our group and other investigators
have shown that first these molecules
were upregulated after IRI, and that their
activation has a negative impact on organ
function outcome (7,8). Indeed, COX
blockade was associated with an im-
provement in renal function and a de-
crease in reactive oxygen species (9,10).
More importantly, the inflammation
triggered by IRI is not restricted to the
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Ischemia and reperfusion injury (IRI) contributes to the development of chronic interstitial fibrosis/tubular atrophy in renal al-
lograft patients. Cyclooxygenase (COX) 1 and 2 actively participate in acute ischemic injury by activating endothelial cells
and inducing oxidative stress. Furthermore, blockade of COX 1 and 2 has been associated with organ improvement after is-
chemic damage. The aim of this study was to evaluate the role of COX 1 and 2 in the development of fibrosis by performing
a COX 1 and 2 blockade immediately before IRI. We subjected C57Bl/6 male mice to 60 min of unilateral renal pedicle oc-
clusion. Prior to surgery mice were either treated with indomethacin (IMT) at days –1 and 0 or were untreated. Blood and kid-
ney samples were collected 6 wks after IRI. Kidney samples were analyzed by real-time reverse transcription–polymerase
chain reaction for expression of transforming growth factor β (TGF-β), monocyte chemoattractant protein 1 (MCP-1), osteo-
pontin (OPN), tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-10, heme oxygenase 1 (HO-1), vimentin, connective-tissue
growth factor (CTGF), collagen I, and bone morphogenic protein 7 (BMP-7). To assess tissue fibrosis we performed morpho-
metric analyses and Sirius red staining. We also performed immunohistochemical analysis of anti-actin smooth muscle. Renal
function did not significantly differ between groups. Animals pretreated with IMT showed significantly less interstitial fibrosis
than nontreated animals. Gene transcript analyses showed decreased expression of TGF-β, MCP-1, TNF-α, IL-1-β, vimentin, col-
lagen I, CTGF, and IL-10 mRNA (all P < 0.05). Moreover, HO-1 mRNA was increased in animals pretreated with IMT (P < 0.05).
Conversely, IMT treatment decreased osteopontin expression and enhanced BMP-7 expression, although these levels did not
reach statistical significance when compared with control expression levels. The blockade of COX 1 and 2 resulted in less tis-
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early days after the insult. Experimental
data have demonstrated that neutrophil
activation and CD4+ T-cell infiltration
persisted 6 wks after the initial injury,
culminating in tissue fibrosis (11,12).
Normally, during the process of tubule-
interstitial remodeling, fibrosis results
from an imbalance between the synthesis
and the degradation of proteins of the
extracellular matrix (13,14) with gradual
loss of renal tubules and their function
(15). Several cytokines participate in fi-
brogenesis, including transforming
growth factor β (TGF-β), platelet-derived
growth factor (PDGF), connective tissue
growth factor (CTGF) (16,17), vimentin
(18), collagen I (19–21), IL-1, fibroblast
growth factor (FGF), osteopontin (OPN),
endothelin, and TNF-α (22). Molecules
such as heme oxygenase 1 (HO-1) and
bone morphogenic protein-7 (BMP-7),
however, are thought to balance the
profibrotic effect of the former molecules.
In the current work, we hypothesized
that COXs also contribute to this cascade
of persistent inflammation. To address
this question, we worked with an estab-
lished model of unilateral IRI. Experi-
mental animals were either pretreated
with a COX inhibitor or not pretreated
before being subjected to acute injury
and followed for 6 wks after injury. We
anticipated that the animals treated with
the COX inhibitor would exhibit the low-
est proinflammatory and profibrotic cy-
tokine levels and have significantly less
tissue fibrosis.
MATERIALS AND METHODS
Unilateral Renal IRI Model
Male C57Bl/6 mice, 10 wks of age
(25–28 g), were purchased from the Ani-
mal Facilities Center from the Institute
of Pharmacology at the Universidade
Federal de São Paulo (São Paulo, Brazil).
The mice were subjected to 60 min uni-
lateral renal pedicle occlusion and were
then monitored for 6 wks after ischemia.
Animals were anesthetized with in-
traperitoneal ketamine and xylazine
(100 mg/kg and 10 mg/kg, respectively;
Agribrands do Brazil, São Paulo, Brazil).
After surgery, animals were housed in
individual cages with free access to
water and food. This project was ap-
proved by the Ethics Committee on
Human and Animal Research of our
institution.
Drug
Mice were treated with IMT (5 mg/kg/d)
1 d before and on the day of surgery (n = 8)
or not treated (n = 8) (23,24). Sham-operated
animals (n = 5) were used as controls.
Functional Analyses
Blood and kidney samples were col-
lected 6 wks after unilateral IRI. 
Assessment of Renal Function
Blood was collected for urea and
serum creatinine measurements, and kid-
neys were harvested for histological and
mRNA analyses at the end points. Urea
was measured in duplicate by the Urease
method and serum creatinine by Jaffe’s
method, using a Cobas Mira Plus auto-
analyzer (Roche, Mannheim, Germany).
The extent of fibrosis was determined by
use of Masson Trichrome stain and per-
formed by blinded morphometric assess-
ment using a computer-assisted image
system with an Olympus BX40F-3 micro-
scope (Olympus Optical, Tokyo, Japan)
and the software program Image Pro
Plus for Windows 3.0 (Media Cybernetic,
Silver Spring, MD, USA). 
Gene Profile
Kidney samples were quickly frozen in
liquid nitrogen. Total RNA was isolated
from kidney tissues using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) meth-
odology. RNA concentration was deter-
mined by spectrophotometer readings at
an absorbance of 260 nm. First-strand
cDNAs were synthesized using moloney
murine leukemia virus reverse transcrip-
tase (Promega, Madison, WI, USA). Re-
verse transcription–polymerase chain re-
action (PCR) was performed using the
SYBR Green real-time PCR assay (Ap-
plied Biosystems, Foster City, CA, USA)
and specific primers for monocyte
chemoattractant protein (MCP)-1 (sense:
5′-ACT GCA TCT GCC CTA AGG TCT
TCA-3′, antisense: 5′-AGA AGT GCT
TGA GGT GGT TGT GGA-3′); IL-1β
(sense: 5´-CCT AAA GTA TGG GCT
GGA CTG TTT-3´, antisense: 5´-TAG AGA
TTG AGC TGT CTG CTC ATT C-3′);
TGF-β (sense: 5′-AAC TAT TGC TTC
AGC TCC AGA GAG A-3′, antisense:
5′-AGT TGG ATG GTA GCC CTT G-3′);
and OPN (sense: 5′-GGC ATT GCC TCC
TCC CTC-3′, antisense: 5′ CGA GGC
TGT AAA GCT TCT CC-3′). We used a




(Mm00516007_m1) (a protective gene,
vimentin (Mm01333430_m1), CTGF
(Mm00515790_g1), and collagen I
(Mm01302047_g1). Hypoxanthine phospho-
ribosyltransferase (HPRT) was used as a
housekeeping gene. PCR data were pre-
sented as a ratio of genes to HPRT
mRNA (sense: 5′-CTC ATG GAC TGA
TTA TGG ACA GGA C-3′ and antisense:
5′-GCA GGT CAG CAA AGA ACT TAT
AGC C-3′ and Mm03024075_m1) in arbi-
trary units (AU).
Immunohistochemical Analysis:
Smooth Muscle Cell Actin Staining
Paraffin block sections (5µm) were
placed on poly-L-lysine–coated slides.
After the sections were dried in an oven
for 1 h at 60°C, they were dewaxed in
xylol for 15 min and hydrated in 3 alco-
hols (100% for 9 min, 95% for 4 min, and
70% for 2 min). Subsequently, sections
were incubated for 10 min in 3% hydro-
gen peroxide to block endogenous per-
oxidase. For antigen retrieval, after
being washed with phosphate-buffered
saline (PBS), each section was unspecifi-
cally blocked. Sections were then incu-
bated overnight at 4°C with anti–actin
smooth muscle (α-SMA; Calbiochem,
Schwalbach, Germany). After a new
wash with PBS for 9 min, the sections
were incubated in a wet chamber for 30
min with a secondary goat anti-mouse
antibody (NCL-GAMP; NovoCastra,
Norwell, MA, USA) and washed with
PBS. Endogenous peroxidase activity
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was detected by reacting fixed tissue
sections with 3.3’-diaminobenzidine sub-
strate plus 10% hydrogen peroxide for
10 min. After being washed with dis-
tilled water, the samples were stained
with hematoxylin for 10 s. Dehydration
was performed with 3 alcohols (70% for
1 min, 95% for 2 min, and 100% for 6
min) and with xylol for 9 min. All quan-
tification was performed blinded. α-SMA
staining was calculated as the percent-
age of renal cortex and medulla. We
used computer image analysis (KS300,
Zeiss system) to measure the percentage
of area occupied by α-SMA staining per
4 mm2 field at a magnification of 200
and calculate the mean percentage area
for each biopsy (25). 
Sirius red staining. Four micra forma-
lin fixed slides were stained with Sirius
red (F3BA CI 35782; Sigma, St. Louis,
MO, USA) 0.1% in saturated picric acid
for 60 min at room temperature. Slides
were washed twice for 5 min in 0.5% gla-
cial acetic acid and counterstained with
Harris hematoxylin. Fibrosis was calcu-
lated as the percentage of renal cortex
and medulla. We used computer image
analysis (KS300, Zeiss system) to measure
the percentage of area occupied by Sirius
red staining per 4 mm2 field at a magnifi-
cation of 200 and calculate the mean per-
centage area calculated for each sample.
Statistics
Data were graphically displayed as
mean and standard deviation (SD) or as
median (histomorphometric analyses)
owing to the Gaussian distribution of
variables. Mann–Whitney U test, Student
t test, and ANOVA on ranks tests were
used to compare the data. PCR data were
presented as a ratio of analyzed genes to
HPRT mRNA, in arbitrary units (AU).
Significant difference was considered
when P < 0.05.
RESULTS
Long-term Renal Function Outcomes
Urea and creatinine levels were mea-
sured at 6 wks following IRI in animals
treated with IMT or otherwise. In this
model, renal function was not altered
significantly and the previous treatment
with IMT did not change these results
(Figure 1A). The ischemic kidneys
weighted significantly less than the
contralateral nonischemic ones, but the
IMT pretreatment did not change this re-
lationship (Figure 1B). Therefore, we
performed morphometric analyses to
quantify tissue fibrosis at this time. In-
terestingly, animals treated with IMT
prior to surgery had less fibrosis com-
pared with nontreated animals (Figure 2).
Sham-operated animals presented basal
levels similar to normal non-manipulated
animals (data not shown).
Cytokine Profiles
As previously seen in renal IRI, as early
as 24 h after reperfusion there is strong
amplification of proinflammatory cytokines
such as IL-1β, TNF-β, and interferon γ. Data
from our laboratory and other groups have
demonstrated that the Th1 immune re-
sponse is deleterious to renal tissue after
IRI (26,27). Therefore, we investigated
the profile of inflammatory cytokines in
ischemic kidneys treated with IMT or oth-
erwise. To compare these results, we also
amplified the transcripts in the contralat-
eral kidneys, as controls.
Ischemic kidneys presented a proin-
flammatory phenotype evidenced by the
higher expression of MCP-1, IL-1β, and
TNF-α (Figure 3). Values for the expres-
sion of these cytokines were even higher
when we compared them with values for
the contralateral kidneys. Interestingly,
animals pretreated with IMT showed a
significant decrease in mRNA expression
consistent with decreased cytokine lev-
els, even in contralateral counterparts.
We also measured IL-10, an anti-
inflammatory cytokine, and HO-1, con-
Figure 2. Morphometric analyses at 6 wks after unilateral IRI. (A) Histological analyses of
kidneys [contralateral (CL) and ischemic kidneys] were performed at 6 wks after 60 min of
unilateral renal ischemia in animals not treated or treated with IMT. *P < 0.05.
Figure 1. Renal function and renal fibrosis after unilateral IRI. (A) Blood urea and serum cre-
atinine levels at 6 wks after 60 min of unilateral renal ischemia, in animals treated with IMT
or not treated. There were no significant differences between groups (P > 0.05). (B) Kidney
weights (in grams) at 6 wks after 60 min of unilateral renal ischemia, in animals treated with
IMT or not treated. There were no significant differences between groups (P > 0.05).
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sidered a protective gene. IMT treatment
decreased IL-10 expression compared
with nontreatment (Figure 4A). Taking
into consideration HO-1 expression, as
previously described in acute renal in-
jury, IMT treatment resulted in an im-
pressive amount of HO-1 upregulation in
this chronic model (Figure 4B).
Fibrotic Changes after IMT Treatment
Pro- and antifibrotic factor expression
can change during the course of renal
IRI. We therefore studied the expression
of these molecules in mice at 6 wks after
ischemia. We analyzed TGF-β, OPN, vi-
mentin, CTGF, and collagen I. These
molecules have previously been shown
to be upregulated in fibrosis (28–31). In
our model, we observed an increase of
mRNA for TGF-β, OPN, vimentin, colla-
gen I, and CTGF in ischemic kidneys
compared with contralateral kidneys.
After IMT treatment, these increased
levels were less evident, but reached sta-
tistical significance for expression of
TGF-β, vimentin, collagen, and CTFG
(Figure 5). The effect of IMT went be-
yond growth factor expression; com-
pared with nontreated ischemic animals,
treated animals showed increases in 
α-SMA staining (Figure 6A) and mir-
rored upregulation in BMP-7 expression,
although these results were not statisti-
cally significant (P > 0.05) (Figure 5C).
These quantitative immunohistochemi-
cal analyses of α-SMA–positive cells cor-
roborated the effects of COX inhibition
on renal tissue fibrosis seen in gene tran-
script analyses (Figure 6A). Furthermore,
IMT-treated animals presented signifi-
cantly less positive Sirius-red staining
than nontreated animals (Figure 6B).
DISCUSSION
IRI is the foremost antigen-independent
factor related to the development of
chronic allograft nephropathy, the leading
cause of graft loss after the first year of
renal transplantation. The inflammation
triggered by IRI, especially in the tubule-
interstitial compartment, results in fibrosis
that is detectable in long-term follow-up
(11). The development of alternative strat-
egies to counteract the development of fi-
brotic tissue is essential for improving
survival of patients who receive trans-
plants from deceased individuals.
In this study, we aimed to demonstrate
that blockade of the COX pathway could
have a beneficial effect in preventing the
development of fibrosis after IRI. Of
note, we performed the COX blockade
prior to acute renal injury. We have pre-
viously demonstrated that a single
episode of severe unilateral warm ische-
mic injury to kidney is associated with
significant long-term kidney inflamma-
tion and development of tissue fibrosis.
These data are in accordance with the
previously reported finding that a single
ischemic episode can lead to mainte-
nance of the inflammatory state, attribut-
able mainly to neutrophils and CD4+
T-cell infiltration. We used a model of se-
vere ischemia to mimic the long-term ef-
fects of ischemia seen in recipients of
kidney transplants from deceased indi-
viduals (32). Lower degrees of ischemia
are less likely to be associated with clini-
cally significant long-term problems.
The extension of tissue damage did
not alter renal function but did decrease
organ size. The histological studies cor-
roborated this finding. At this point, the
IMT treatment had no effect on organ
size but had a great impact on the devel-
opment of fibrosis. Histomorphometric
analyses showed that less fibrosis was
seen in IMT-treated animals. These re-
sults indicate that early inflammation in-
duced by ischemic stress leads to long-
term fibrosis development, as previously
demonstrated (11), and more impor-
tantly, the blockade of this early-onset in-
flammation is beneficial in halting this
process.
Figure 3. Proinflammatory cytokine profile at 6 wks after unilateral IRI. mRNA levels of
MCP 1 (A, *P < 0.05), IL-1β (B, *P = 0.013), and TNF-α (C, *P = 0.029 and **P = 0.028) in con-
tralateral and ischemic kidneys in animals treated or not with IMT. mRNAs were standard-
ized for HPRT mRNA and were expressed as AU.
Figure 4. Anti-inflammatory profile at 6 wks after unilateral IRI. mRNA levels of IL-10 (A, *P =
0.03) and HO-1 (B, *P < 0.05) in contralateral and ischemic kidneys in animals treated or
not with IMT. mRNA was standardized for HPRT mRNA and expressed as AU.
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Because inflammation seems to be
linked with fibrogenesis in our model,
we opted to quantify a broad range of
proinflammatory cytokines/growth fac-
tors and of BMP-7, HO-1, and IL-10,
molecules that can counteract the actions
of proinflammatory cytokines/growth
factors.
It is well established that fibrogenesis
results from an imbalance between
growth factors and cytokines such as
TGF-β, PDGF, CTGF, collagen I, OPN,
FGF, IL-1α and -1β, and BMP-7 (16–21,
33–35). Proximal epithelial cells as well
as infiltrating cells may produce these
molecules, stimulated by the reactive
oxygen species secreted by the injured
cells (36,37). Vimentin has also been
linked to fibrogenesis in the kidney (18)
and to epithelial-to-mesenchymal tran-
sition (EMT) (38,39). These injured
proximal tubular cells seem to release
chemotactic factors, such as MCP-1,
which promotes leukocyte attachment
to tubular lumen and infiltration into
the interstitium, amplifying this inflam-
matory cascade (40). Gloria and col-
leagues have demonstrated in an in
vitro cell model of gaseous hypoxia that
COX blockade decreased the expression
of RANTES (regulated on activation
normal T-cell expressed and secreted),
another chemokine involved in leuko-
cyte transmigration (41). Our data
demonstrated that the animals pre-
treated with IMT presented less MCP-1
expression, a finding that supports this
hypothesis.
Pretreatment with IMT significantly
decreased the levels of proinflammatory
cytokines, including IL-1β and TNF-α.
The production of IL-1β by the glomeru-
lar cells is increased in several types of
clinical and experimental glomerulopa-
thy in which fibrosis occurs. IL-1β stimu-
lates the proliferation of fibroblasts and
possibly the synthesis of extracellular
matrix proteins, and it also has a chemo-
tactic effect. Importantly, treatment with
IL-1β antagonists reduces fibrosis in rats
with glomerulonephritis (42). Further-
more, Stanimirovic et al. demonstrated
that in cerebral IRI COX inhibition by
IMT reduced neutrophil adhesion and
completely inhibited IL-1β mRNA ex-
pression (43). Thus, we can infer that the
decreased extension of fibrosis may be
partly attributable to decreased expres-
sion of these molecules owing to the ac-
tion of IMT.
When we analyzed the profile of pro-
and antifibrotic molecules, we observed
that after 6 wks of reperfusion ischemic
kidney tissue exhibited increased expres-
sion of profibrotic factors, namely TGF-β,
vimentin, collagen I, CTGF, and OPN.
The effect of IMT on TGF-β expression is
important given the critical role of TGF-β
in renal fibrosis. The EMT (44) may be
attributable to TGF-β inducing myofi-
broblast transformation and increasing
collagen synthesis. The present study
demonstrated that COX inhibition can
actually decrease TGF-β expression, a de-
crease associated with signs of decreased
tissue fibrosis. Additional studies should
be carried out to ascertain whether COX
accelerates EMT. The expression of OPN,
collagen I, and α-SMA were in accor-
dance with that of TGF-β. α-SMA is ex-
pressed during EMT and is a marker of
“activated” fibroblasts. Therefore, IMT
could decrease the fibrosis by reducing
these cells in the interstitium. The reduc-
tion in OPN expression indicates, be-
yond the reduction of fibrosis, lower
macrophage infiltration, because OPN is
considered one of the chemokines that
attracts macrophages into the injured
renal tissue (45). Macrophage infiltration
correlates with the development of fibro-
sis (46–49). Finally, TGF-β signaling is
regulated by BMP-7, also a member of
the TGF-β family, through activation
of Smad-6. This regulation can inhibit
EMT (50).
Vimentin is a transitional filament
protein mainly expressed in mesenchy-
mal-derived cells. It can be reexpressed
in renal tubular epithelial cells under
many pathological conditions such as is-
chemia. Terzi and colleagues demon-
strated that vimentin expression is up-
regulated after renal ischemia in
proximal tubular cells (51). CTGF seems
Figure 5. Pro- and antifibrotic profile at 6 wks after unilateral IRI. mRNA levels of TGF-β (A,
*P < 0.05), OPN (B, *P < 0.05), BMP-7 (C, *P < 0.05), vimentin (D, *P < 0.05), collagen I (E, *P <
0.05), and CTGF (F, *P < 0.05) in contralateral and ischemic kidneys in animals treated or not
with IMT. mRNA was standardized for HPRT mRNA and expressed as AU.
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to be responsible for some TGF-β profi-
brotic activities (52). Nguyen and Gold-
schmeding have recently proposed that
CTGF inihibition or BMP-7 induction
could be a future therapy for renal fibro-
sis (52). Nguyen and Goldschmeding
showed that BMP-7 expression was di-
minished in the ischemic kidneys com-
pared with the contralateral kidneys and
that treatment with IMT reversed BMP-7
expression, albeit without reaching sta-
tistical significance, and that IMT signifi-
cantly decreased CTGF expression. These
results could be promising because we
have already observed that in animals
treated with rapamycin and then sub-
jected to unilateral ureteral obstruction, a
model of renal fibrosis, the increased ex-
pression of BMP-7 was associated with
less renal fibrosis (53). The blockade of
CTGF has also been showed to be protec-
tive in reducing fibrosis in a unilateral
ureteral obstruction model (54).
The action of proinflammatory cy-
tokines could also be antagonized by fa-
voring a Th2 immune response or by en-
hancing innate cellular protective gene
machinery. We analyzed the expression
of IL-10, an anti-inflammatory cytokine,
and HO-1, a protective gene. Some stud-
ies have shown that the increase of IL-10
expression diminishes intercellular adhe-
sion molecule 1 and selectins (55,56),
which are both responsible for neu-
trophil rolling in the endothelium, pro-
tecting the kidney from IRI. Furthermore,
the inhibition of these molecules by
chemical drugs or in knockout animals is
associated with tissue protection (57).
Consequently, we investigated whether
treatment with IMT would have an influ-
ence on expression of HO-1 and IL-10.
We observed an increase of HO-1 in the
ischemic kidneys; however, this increase
was visibly higher when the animals
were treated with IMT. These data cor-
roborate our observation that pretreat-
ment with IMT in animals was associ-
ated with a sustained increase in HO-1
following an acute renal injury (3). Con-
versely, IL-10 expression was increased
in ischemic kidneys but was reduced
when the animals were pretreated with
IMT. Although IL-10 and HO-1 can in-
hibit proinflammatory genes associated
with activation of monocytes/
macrophages, such as TNF-α, IL-1-β,
and granulocyte-macrophage–colony-
stimulating factor, in some specific mod-
els the anti-inflammatory effects of HO-1
seem to be independent of those of IL-10.
Prostaglandin E2 can also have anti-in-
flammatory properties through induction
of IL-10 (58,59), and the data expression
found with IL-10 could be a reflection of
an already protective response initiated
by the organ after the initial injury. This
response, however, is not strong enough
to halt fibrosis. In this sense, the protec-
tion seen with IMT seems to be HO-1 de-
pendent and IL-10 independent.
Recent data have established that IRI is
an inflammatory syndrome and, more
importantly, that the inflammatory re-
sponse of IRI is persistent, culminating in
the development of fibrosis. Renal fibro-
sis is the final pathway of many diseases,
and no known treatment can halt or
regress it. Our results demonstrated that
COX 1 and 2 play an important role in
the development of sustained inflamma-
tion. Their blockade prior to an acute in-
jury could be beneficial in limiting the
renal damage caused by fibrosis.
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